Loading organizations...
§ Private Profile · Los Angeles, CA, USA
Academic institute providing eye care, vision research, and ophthalmology education.
Key people at David Geffen School of Medicine at UCLA - Stein Eye Institute.
The David Geffen School of Medicine at UCLA - Stein Eye Institute is a Los Angeles, California-based academic medical center that provides comprehensive ophthalmology care, conducts vision-science research, and offers medical training. Operating as a public institution within the broader university system, the institute recently expanded its clinical and research capabilities through a $65 million renovation of its primary facility to support advanced treatments. The broader medical school benefits from significant philanthropic backing, including a $200 million endowment from entertainment executive David Geffen. Throughout its history, the institute has been shaped by notable figures such as longtime director Bartly Mondino and pioneering faculty member Patricia Bath, who invented the Laserphaco device for cataract surgery. The David Geffen School of Medicine at UCLA - Stein Eye Institute was founded in 1966 by Jules Stein and Bradley R. Straatsma.
The David Geffen School of Medicine at UCLA's Stein Eye Institute is a premier ophthalmology research and clinical care center dedicated to preventing blindness and advancing vision science. It provides comprehensive patient care, cutting-edge research, education, and community outreach focused on eye diseases and vision preservation. The Institute serves patients with a wide range of eye conditions while driving innovations in ophthalmic treatments and therapies, maintaining a strong growth trajectory through program expansions and affiliations with other leading eye care institutions[1][2][5].
Founded in 1966 by Jules Stein, an ophthalmologist and entertainment industry pioneer, and Bradley R. Straatsma, the founding chairman of UCLA's Department of Ophthalmology, the Stein Eye Institute emerged from Stein’s vision to combat blindness through integrated research, education, and clinical care. Stein’s philanthropic leadership, alongside his wife Doris, was instrumental in establishing the Institute as a multidisciplinary hub. Early milestones included securing major funding, building state-of-the-art facilities, and forging key partnerships, such as the affiliation with the Doheny Eye Institute in 2013, which expanded its research and clinical capabilities[1][2][4][7].
The Stein Eye Institute rides the trend of precision medicine and translational research in ophthalmology, leveraging advances in genetics, gene therapy, and biomedical engineering to address complex eye diseases. The timing is critical as the global burden of vision impairment grows with aging populations, increasing demand for innovative treatments. The Institute influences the broader ecosystem by setting standards in eye care, fostering interdisciplinary collaboration, and contributing to national vision research priorities, including support for the National Eye Institute and Research to Prevent Blindness[1][2][8].
Looking ahead, the Stein Eye Institute is poised to expand its impact through emerging therapies such as gene editing and regenerative medicine. Continued investment in research infrastructure and faculty growth will likely enhance its leadership in ophthalmology. Trends in digital health and artificial intelligence may further transform diagnostics and patient management at the Institute. Its enduring influence will stem from balancing cutting-edge innovation with comprehensive patient care, education, and community engagement, fulfilling Jules Stein’s original vision to prevent blindness worldwide[1][7].
Key people at David Geffen School of Medicine at UCLA - Stein Eye Institute.
